Evogene (EVGN) Common Equity (2016 - 2025)
Evogene (EVGN) has disclosed Common Equity for 10 consecutive years, with -$82000.0 as the latest value for Q4 2025.
- Quarterly Common Equity rose 94.35% to -$82000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$82000.0 through Dec 2025, up 94.35% year-over-year, with the annual reading at -$82000.0 for FY2025, 94.35% up from the prior year.
- Common Equity hit -$82000.0 in Q4 2025 for Evogene, up from -$1.5 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $53.7 million in Q4 2021 to a low of -$1.5 million in Q4 2024.
- Historically, Common Equity has averaged $18.4 million across 5 years, with a median of $12.1 million in 2023.
- Biggest five-year swings in Common Equity: surged 395.09% in 2021 and later tumbled 112.04% in 2024.
- Year by year, Common Equity stood at $53.7 million in 2021, then crashed by 47.94% to $27.9 million in 2022, then tumbled by 56.85% to $12.1 million in 2023, then crashed by 112.04% to -$1.5 million in 2024, then soared by 94.35% to -$82000.0 in 2025.
- Business Quant data shows Common Equity for EVGN at -$82000.0 in Q4 2025, -$1.5 million in Q4 2024, and $12.1 million in Q4 2023.